SCHEMBL1714584

SCHEMBL1714584

CCOCCCN1C(=O)C(=Cc2c[nH]c3ncccc23)N=C1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 2/20 0.41
▸ KMT2A Q03164 1/20 0.40
▸ HASPIN Q8TF76 4/20 0.40
▸ CCNT1 O60563 2/20 0.40
▸ CDK9 P50750 2/20 0.40
▸ CDC7 O00311 7/20 0.38
▸ PIM1 P11309 1/20 0.36
▸ PIM3 Q86V86 1/20 0.36
▸ PIM2 Q9P1W9 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PDPK1 O15530 1/20 0.35
▸ CHEK2 O96017 1/20 0.35
▸ CDK1 P06493 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ CSNK2A2 P19784 1/20 0.35
▸ CSNK2B P67870 1/20 0.35
▸ CSNK2A1 P68400 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714583 1.00 CHEK1 (0.41) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714255 0.85 CHEK1 (0.42) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714257 0.85 CHEK1 (0.42) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713725 0.82 CHEK1 (0.41) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713727 0.82 CHEK1 (0.41) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714398 0.80 CDC7 (0.42) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714401 0.80 CDC7 (0.42) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714105 0.78 KMT2A (0.47) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714107 0.78 KMT2A (0.47) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714276 0.73 KMT2A (0.44) CHEK1KMT2AHASPINCCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 — — US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 — — EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 CHEK1 17/4885KMT2A 3256/4885HASPIN 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback